AbbVie submits FDA application for etentamig after Phase 3 CERVINO success in multiple myeloma
AbbVie seeks FDA approval for etentamig after Phase 3 myeloma results showed a 60% reduction in progression risk. Infection safety remains in focus.
Pharma & Biotech